European Union pharmaceutical legislation reform

The Council of the European Union has adopted a major pharmaceutical reform package, representing the most significant update to EU drug laws in over twenty years. The legislation is designed to ensure equitable access to safe, effective, and affordable medicines while enhancing the competitiveness of the European pharmaceutical sector and strengthening supply security.

Key components of the reform include a standardized eight-year data protection period for new medicines. This period can be extended by up to three additional years—reaching a maximum of eleven years—if specific criteria are met, such as addressing unmet medical needs or conducting comparative clinical trials. In cases involving the development of priority antibiotics to combat antimicrobial resistance, the total protection period may be extended to twelve years.

To mitigate supply shortages, EU member states will be granted the authority to require pharmaceutical companies to provide sufficient quantities of essential medicines. The reform also aims to reduce bureaucracy by shortening the European Medicines Agency’s review timelines from 210 to 180 days and introducing electronic patient leaflets. Additionally, the framework facilitates faster market entry for generic and biosimilar drugs by allowing manufacturers to conduct necessary studies before original intellectual property protections expire.